<DOC>
	<DOCNO>NCT02342275</DOCNO>
	<brief_summary>The purpose study compare efficacy orally administer propranolol versus atenolol treatment potentially disfigure functionally threaten IHs .</brief_summary>
	<brief_title>Efficacy Safety Propranolol Versus Atenolol Proliferative Phase Infantile Hemangioma</brief_title>
	<detailed_description>Currently , propranolol prefer treatment problematic proliferating infantile hemangioma ( IHs ) . Although propranolol clearly efficacious , rare side effect , hypoglycemia , may life-threatening . The possibility propranolol resistance treatment failure also important , highlight need employ establish technique certain case . Nonselective β-adrenergic antagonist , propranolol timolol , competitive antagonist catecholamines β1- β2-adrenergic receptor ( β-ARs ) . β2-AR blockade may result hypoglycemia result decrease glycogenolysis , gluconeogenesis , lipolysis . Moreover , bronchial hyperreactivity direct effect nonselective β-blockers , result bronchospasm due pulmonic β2-AR blockade . A solution minimize many side effect nonselective β-blocker therapy may use selective β1-blockers metoprolol atenolol , , low dosage , little β2 activity . Unfortunately , paucity clinical data compare efficacy selective non-selective β-blocker . Furthermore , broad heterogeneity IH ( e.g. , proliferate versus involuting ) , confound pharmacologic exposure ( e.g. , corticosteroid ) , associate complication ( e.g. , ulceration ) comorbid medical anomaly ( e.g. , PHACE ) influence efficiency IH treatment , observational study unable definitively establish clinical utility β-blockers IH . Thus , question regard efficacy subtypes β-blockers must answer randomize controlled trial , may provide way overcome selection ascertainment bias . The purpose study compare efficacy orally administer propranolol versus atenolol treatment potentially disfigure functionally threaten IHs .</detailed_description>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Hemangioma , Capillary</mesh_term>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Patients young 24 week . Presenting hemangioma follow characteristic : Subcutaneous and/or cutaneous Minimum diameter 1.5 cm face , 3 cm outside face 1.5 cm ulcerated . Consent parent ( person parental authority family ) Infant present contraindication administration propranolol atenolol . Hemangioma previous treat corticosteroid , laser , cryotherapy , treatment . Patients inability participate follow study treatment assessment plan .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Weeks</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Infantile hemangioma</keyword>
	<keyword>Propranolol</keyword>
	<keyword>Atenolol</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>